Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study

BACKGROUND: The aim of this study was to evaluate the bioequivalence of the test and reference products of ibrutinib capsule (140 mg). RESEARCH DESIGN AND METHODS: ) estimated in the study. RESULTS: ) met the bioequivalence acceptance criteria in both fasting and fed studies. CONCLUSIONS: of ibrutinib. CLINICAL TRIAL REGISTRATION: http://www.chinadrugtrials.org.cn/index.html identifier is CTR20202168.